Brazil’s tax reform introduces structural changes affecting corporate financial planning. For the pharmaceutical sector, a key point of focus involves the dynamics of the Positive List (Lista Positiva), which classifies certain medicines for tax purposes, and the application of unconditional discounts, which are granted at the time of sale without depending on future events.
The Phase-Out of PIS and Cofins
With the overhaul of the tax system, existing levies will undergo a replacement process. The debate on pharmaceutical taxation is especially relevant due to the planned phase-out of PIS (Social Integration Program) and Cofins (Contribution for the Financing of Social Security).
Credit Transition to CBS in 2027
The phase-out of these taxes is directly linked to the transition of their respective tax credits to the new CBS (Contribution on Goods and Services). This shift is scheduled to take place in 2027.
This structural change requires pharmaceutical companies to closely observe how credits tied to Positive List products will be treated. Likewise, the accounting and impact of unconditional discounts must be reviewed during the transition to the new tax model.
Practical Impact
The horizon leading up to 2027 indicates that pharmaceutical companies, executives, and investors must monitor the regulatory details of this transition. Properly adjusting credits during the shift from PIS/Cofins to the CBS will be an essential step to ensure ongoing tax compliance for operations in the sector.
This content is for informational purposes only and does not constitute legal advice. For guidance on specific matters, consult a qualified lawyer.
Deixe um comentário